Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study
Ben Beaglehole, Paul Glue, Shona Neehoff, Shabah M. Shadli, Neil McNaughton, Bridget Kimber, Corinne Muirhead, Aroha de Bie, Rachel Day-Brown, Natalie J. Medlicott
BJPsych Open October 1, 2025 DOI: 10.1192/bjo.2025.10854 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Clinical trial Randomized Double-blind Peer reviewed |
|---|---|
| Population | Community sample of individuals with PTSD |
| Intervention | Ketamine |
| Topics | Ketamine Esketamine PTSD |
| Keywords | Tolerability Dosing Crossover study Regimen Fight-or-flight response Clinical trial Anesthesia Placebo Context archaeology Randomized controlled trial Stress linguistics |
| Citations | 5 |
| Key findings | Intramuscular ketamine demonstrates preliminary efficacy and tolerability in a community sample of individuals with PTSD. |
Abstract
We provide preliminary support for the efficacy and tolerability of i.m. ketamine in a community sample of individuals with PTSD. Further work is required to establish the optimal dosing regimen and longer-term role of ketamine in treatment of PTSD, but our findings are encouraging given the well-known of treatments in this area.